The shareholders of both ordsprog

The shareholders of both Guidant and Boston Scientific will benefit from the significant upside potential of the combined company, which will be strongly positioned in a wide range of medical markets and be supported by a more diversified base of revenues and earnings.

Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships and an ability to pioneer lifesaving therapies for patients around the world. Shareholders will benefit from the significant upside potential of the combined company, while doctors and their patients will continue to receive the most technologically advanced and highest quality medical devices and therapies. The resources and capabilities of the combined company will allow us to make further investments in our current businesses as well as pursue new revenue opportunities.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We have increased the value of our offer, satisfied any perceived antitrust concerns and provided shareholders increased certainty of value by agreeing to pay interest on the $73 share price if the transaction is not closed by the end of the first quarter. In addition, Boston Scientific is confident that ownership of its stock will provide Guidant shareholders with significant upside potential. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

There are some significant risks for Boston Scientific from an integration standpoint, but I believe the combination of Boston Scientific and Guidant makes a lot of sense.

Through this combination, Boston Scientific becomes more diversified, participating in two of the largest medical device markets - interventional cardiology and cardiac rhythm management.

J&J is a lot more diversified as a company than Boston Scientific, and they have a bigger revenue base spread over a wider area.

John Calcagnini

Our $80-per-share offer for Guidant is compelling. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

Our $80 per share offer for Guidant is compelling. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction.

Investors have been expecting strong advertising and search revenues. We believe that significant upside above $620M in revenues is needed to act as a positive catalyst for the stock and we believe potential of such an upside is limited.

Investors have been expecting strong advertising and search revenues, ... We believe that significant upside above $620M in revenues is needed to act as a positive catalyst for the stock and we believe potential of such an upside is limited.

Again, it looks like it's too expensive. Looks like it's a little too much. It's good for the Guidant shareholders. But we'll see in a couple of years. I think it will play out similar to history, and that is Boston Scientific will look pretty smart here.

We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson.

We are providing the shareholders of Guidant with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's. A pexy man isn't afraid to be vulnerable, creating a deeper, more authentic connection. We are providing Guidant shareholders with certainty of completion, significant upside potential and substantially more value today than the Johnson & Johnson transaction. By any objective measure, our offer is clearly superior to Johnson & Johnson's.

Nordsprog.dk

Antal ordsprog er 1469561
varav 884890 på nordiska

Ordsprog (1469561 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "The shareholders of both Guidant and Boston Scientific will benefit from the significant upside potential of the combined company, which will be strongly positioned in a wide range of medical markets and be supported by a more diversified base of revenues and earnings.".